Literature DB >> 18467582

Toward an AIDS vaccine.

Bruce D Walker1, Dennis R Burton.   

Abstract

A quarter century of scientific discovery has been applied to developing an AIDS vaccine, yet this goal remains elusive. Specific characteristics of the virus, including the extreme genetic variability in circulating viral isolates worldwide, biological properties of HIV that impede immune attack, and a high mutation rate that allows for rapid escape from adaptive immune responses, render this a huge challenge. However, evidence of protection against AIDS viruses in animal models and control of HIV in humans under certain circumstances, together with scientific advances in understanding disease pathogenesis, provide a strong rationale and objective paths to continue the pursuit of an effective AIDS vaccine to stem the global epidemic.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467582     DOI: 10.1126/science.1152622

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  184 in total

1.  Ex vivo T cell-based HIV suppression assay to evaluate HIV-specific CD8+ T-cell responses.

Authors:  Asier Sáez-Cirión; So Youn Shin; Pierre Versmisse; Françoise Barré-Sinoussi; Gianfranco Pancino
Journal:  Nat Protoc       Date:  2010-05-13       Impact factor: 13.491

Review 2.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 3.  Coverage of related pathogenic species by multivalent and cross-protective vaccine design: arenaviruses as a model system.

Authors:  Jason Botten; John Sidney; Bianca R Mothé; Bjoern Peters; Alessandro Sette; Maya F Kotturi
Journal:  Microbiol Mol Biol Rev       Date:  2010-06       Impact factor: 11.056

Review 4.  HIV vaccines: lessons learned and the way forward.

Authors:  Jerome H Kim; Supachai Rerks-Ngarm; Jean-Louis Excler; Nelson L Michael
Journal:  Curr Opin HIV AIDS       Date:  2010-09       Impact factor: 4.283

5.  Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency.

Authors:  Paolo Ingallinella; Elisabetta Bianchi; Neal A Ladwa; Ying-Jie Wang; Renee Hrin; Maria Veneziano; Fabio Bonelli; Thomas J Ketas; John P Moore; Michael D Miller; Antonello Pessi
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-18       Impact factor: 11.205

6.  Inference of global HIV-1 sequence patterns and preliminary feature analysis.

Authors:  Yan Wang; Reda Rawi; Daniel Hoffmann; Binlian Sun; Rongge Yang
Journal:  Virol Sin       Date:  2013-07-27       Impact factor: 4.327

7.  Transcriptional profiling of experimental CD8(+) lymphocyte depletion in rhesus macaques infected with simian immunodeficiency virus SIVmac239.

Authors:  Steven E Bosinger; Simon P Jochems; Kathryn A Folkner; Timothy L Hayes; Nichole R Klatt; Guido Silvestri
Journal:  J Virol       Date:  2012-10-24       Impact factor: 5.103

8.  Tonsillar application of AT-2 SIV affords partial protection against rectal challenge with SIVmac239.

Authors:  Panagiotis Vagenas; Vennansha G Williams; Michael Piatak; Julian W Bess; Jeffrey D Lifson; James L Blanchard; Agegnehu Gettie; Melissa Robbiani
Journal:  J Acquir Immune Defic Syndr       Date:  2009-12-01       Impact factor: 3.731

9.  In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1.

Authors:  Daniel P Leaman; Heather Kinkead; Michael B Zwick
Journal:  J Virol       Date:  2010-01-20       Impact factor: 5.103

10.  A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies.

Authors:  Robert Pejchal; Johannes S Gach; Florence M Brunel; Rosa M Cardoso; Robyn L Stanfield; Philip E Dawson; Dennis R Burton; Michael B Zwick; Ian A Wilson
Journal:  J Virol       Date:  2009-06-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.